Cisapride is a gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract. It acts directly as a serotonin 5-HT4 receptor agonist and indirectly as a parasympathomimetic. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system.
Earlier identification of potential toxicity delivers the greatest financial benefits for the chemical producing industries by reducing the massive costs of downstream failures that occur at all phases of development.
- AsedaSciences can help predict the hidden safety risks and accelerate informed decisions making on weather to Approve, Improve or Remove™ a compound from the R&D pipeline.
- 25-30% of potential therapeutic compounds entering Phase II and Phase III clinical trials fail due patient safety concerns, ultimately costing the pharmaceutical industry billions of dollars.
- By predicting risk of compound toxicity at the start of Drug Discovery, chemist can design safer drugs that will assist in improving the quality of the drug discovery pipeline. This in turn will help reduce the financial burden of later stage failures, reduce and refine the use of animals and minimize the safety risk to patients.